 Entera Bio Ltd NASDAQ: ENTX is soaring in the premarket in reaction to positive topline data from the Phase 2 trial of EB613 in postmenopausal female subjects with osteoporosis low bone mineral density. Three-month bone biomarker data analysis showed a significant increase in the P1NP biomarker in the 2.5 mg dose group after three months of treatment compared to placebo. 